A systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulants vs vitamin K antagonists after transcatheter aortic valve replacement in patients with atrial fibrillation

Ooi, Amanda Jia Qi; Wong, Chloe; Tan, Timothy Wei Ern; Ng, Trina Priscilla; Teo, Yao Neng; Teo, Yao Hao; Syn, Nicholas; Djohan, Andie Hartanto; Lim, Yinghao; Yeo, Leonard Ll; Tan, Benjamin Yq; Chan, Mark Y; Poh, Kian‐Keong; Kong, William; Chai, Ping; Yeo, Tiong‐Cheng; Yip, James; Kuntjoro, Ivandito; Sia, Ching‐Hui

doi:10.1007/s00228-022-03371-6

Cited by 1 publication

(2 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A meta-analysis found that NOACs had lower risks of all-cause mortality and bleeding than VKAs at 1 year after TAVI in AF patients. 33 Another meta-analysis conducted by Memon et al showed no significant difference in stroke or systemic embolism, all-cause mortality, major bleeding, intracranial hemorrhage, and myocardial infarction between NOACs versus VKAs for AF patients undergoing TAVI. 32 Our meta-analysis revealed that the patients prescribed NOACs had a lower incidence of bleeding and intracranial bleeding.…”

Section: Discussionmentioning

confidence: 99%

“…To date, the latest guidelines do not specify the preference of NOACs or VKAs for anticoagulant therapy in AF patients after TAVI. 1 Although the meta-analyses on the clinical outcomes of NOACs versus VKAs after TAVI in patients with AF have been published, 32,33 the search was more comprehensive with an increase in the number of patients enrolled and only studies with AF patients accounting for more than 90% of all TAVI patients were included in our meta-analysis. Most importantly, the results of our meta-analysis differed from those metaanalyses.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and Safety of NOACs Compared With VKAs for Patients With Atrial Fibrillation After Transcatheter Aortic Valve Implantation: A System Review and Meta-Analysis

Han

et al. 2022

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

Novel oral anticoagulants (NOACs) are preferentially recommended in patients with nonvalvular atrial fibrillation (AF) for stroke prevention over vitamin K antagonists (VKAs). However, the evidence regarding the efficacy and safety of NOACs versus VKAs after transcatheter aortic valve implantation (TAVI) in patients with AF is very rare. Pubmed, Embase, Web of science, and Cochrane Databases were searched for eligible studies published before May 19, 2022. A total of 11 studies were included in this meta-analysis involving 27 107 patients. Regarding primary outcomes, there were no differences between NOACs and VKAs in all-cause mortality ( RR: 0.84, 95% CI: (0.69, 1.02)) and stroke ( RR: 1.00, 95% CI: (0.85, 1.19)). With respect to secondary outcomes, NOACs were associated with reduced incidence of bleeding ( RR: 0.77, 95% CI: (0.71, 0.83)) and intracranial bleeding ( RR: 0.57, 95% CI: (0.39, 0.83)), whereas no significant differences were found in major or life-threatening bleeding ( RR: 0.98, 95% CI: (0.82, 1.17)) and myocardial infarction ( RR: 1.37, 95% CI: (0.83, 2.26)). Our meta-analysis revealed the safety and efficacy of NOACs may be superior to VKAs in AF patients undergoing TAVI.

show abstract

Section: Discussionmentioning

confidence: 99%